Frailty and Cancer Prognosis.

IF 4.7 2区医学 Q1 ONCOLOGY

Current Oncology Reports Pub Date : 2024-09-01 Epub Date: 2024-06-12 DOI:10.1007/s11912-024-01558-x

Ana Patricia Navarrete-Reyes, Abigail Samayoa Mateos-Soria, Juan José Sánchez-Hernández, Juan Pablo Negrete-Najar

{"title":"Frailty and Cancer Prognosis.","authors":"Ana Patricia Navarrete-Reyes, Abigail Samayoa Mateos-Soria, Juan José Sánchez-Hernández, Juan Pablo Negrete-Najar","doi":"10.1007/s11912-024-01558-x","DOIUrl":null,"url":null,"abstract":"Purpose of review: This review aims to summarize the current evidence regarding the prognostic role of frailty in older patients diagnosed with cancer and to explore the evidence regarding its prognostic implications in cancer survivors.Recent findings: Frailty has been consistently associated with mortality/overall survival, postoperative complications, short- and long-term postoperative mortality, length of stay, among other adverse health-related outcomes in several oncological contexts. The possible association between frailty and treatment toxicity has been less explored, however most studies suggest frailty is a predictor of treatment induced toxicity. In addition, in cancer survivors, frailty is a risk factor for cardiovascular disease, incident type 2 diabetes mellitus, mortality, altered cognitive performance and increased symptom severity. Due to its usefulness in establishing prognosis and informing treatment decision making, it is expected that frailty screening and assessment will continue to gain popularity as part of the pretreatment evaluation of older patients with cancer.","PeriodicalId":10861,"journal":{"name":"Current Oncology Reports","volume":" ","pages":"991-1020"},"PeriodicalIF":4.7000,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Oncology Reports","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11912-024-01558-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/6/12 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose of review: This review aims to summarize the current evidence regarding the prognostic role of frailty in older patients diagnosed with cancer and to explore the evidence regarding its prognostic implications in cancer survivors.

Recent findings: Frailty has been consistently associated with mortality/overall survival, postoperative complications, short- and long-term postoperative mortality, length of stay, among other adverse health-related outcomes in several oncological contexts. The possible association between frailty and treatment toxicity has been less explored, however most studies suggest frailty is a predictor of treatment induced toxicity. In addition, in cancer survivors, frailty is a risk factor for cardiovascular disease, incident type 2 diabetes mellitus, mortality, altered cognitive performance and increased symptom severity. Due to its usefulness in establishing prognosis and informing treatment decision making, it is expected that frailty screening and assessment will continue to gain popularity as part of the pretreatment evaluation of older patients with cancer.

查看原文本刊更多论文

虚弱与癌症预后

综述的目的：本综述旨在总结目前有关虚弱对确诊癌症的老年患者预后作用的证据，并探讨有关虚弱对癌症幸存者预后影响的证据：最近的研究结果：在一些肿瘤研究中，体弱一直与死亡率/总生存率、术后并发症、短期和长期术后死亡率、住院时间以及其他与健康相关的不良后果有关。关于虚弱与治疗毒性之间可能存在的关联的研究较少，但大多数研究表明，虚弱是治疗毒性的一个预测因素。此外，在癌症幸存者中，虚弱是心血管疾病、2 型糖尿病、死亡率、认知能力改变和症状严重程度增加的风险因素。由于虚弱程度筛查和评估有助于确定预后并为治疗决策提供信息，预计它将继续作为老年癌症患者预处理评估的一部分而受到欢迎。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Oncology Reports ONCOLOGY-

CiteScore

8.50

自引率

0.00%

发文量

187

审稿时长

6-12 weeks

期刊介绍： This journal aims to review the most important, recently published clinical findings in the field of oncology. By providing clear, insightful, balanced contributions by international experts, the journal intends to serve all those involved in the care of those affected by cancer. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as cancer prevention, leukemia, melanoma, neuro-oncology, and palliative medicine. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.